Structure-based design of 7-azaindole-pyrrolidine amides as inhibitors of 11β-hydroxysteroid dehydrogenase type i

Bioorganic and Medicinal Chemistry Letters

Volumn 22, Issue 18, 2012, Pages 5909-5914

  Valeur, Eric ^a,c   Christmann Franck, Serge ^a   Lepifre, Franck ^a,d   Carniato, Denis ^a   Cravo, Daniel ^a,e   Charon, Christine ^a,d   Bozec, Sophie ^a,e   Musil, Djordje ^b   Hillertz, Per ^b,f   Doare, Liliane ^a   Schmidlin, Fabien ^a,g   Lecomte, Marc ^a   Schultz, Melanie ^b   Roche, Didier ^a,h  

^a MERCK SERONO S A   (Switzerland)

^b Merck Serono GmbH   (Germany)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Metabrain Research   (France)

^e Poxel Pharma   (France)

^f ASTRAZENECA R AND D   (Sweden)

^g IPSEN   (France)

^h Edelris   (France)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 11BETA HYDROXYSTEROID DEHYDROGENASE 2; 7 AZAINDOLE PYRROLIDINE AMIDE DERIVATIVE; INDOLE DERIVATIVE; PYRROLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CRYSTAL STRUCTURE; DRUG CLEARANCE; DRUG DESIGN; DRUG DETERMINATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; IC 50; MOUSE; NONHUMAN; X RAY;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; AMIDES; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; INDOLES; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PYRROLIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84865488099     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2012.07.070     Document Type: Article

References (34)

1. S. Nobel, L. Abrahmsen, and U. Oppermann Eur. J. Biochem. 268 2001 4113
2. J.W. Tomlinson, E.A. Walker, I.J. Bujalska, N. Draper, G.G. Lavery, M.S. Cooper, M. Hewison, and P.M. Stewart Endocrinol. Rev. 25 2004 831
3. P.S. Brereton, R.R. van Driel, F. Suhaimi, K. Koyama, R. Dilley, and Z. Krozowski Endocrinology 142 2001 1644
4. I.J. Bujalska, S. Kumar, and P.M. Stewart Lancet 349 1997 1210
5. P.H. Jellinck, C. Pavlides, R.R. Sakai, and B.S. McEwen J. Steroid. Biochem. Mol. Biol. 71 1999 139
6. M.M. Moisan, J.R. Seckl, and C.R.W. Edwards Endocrinology 127 1990 1450
7. M.L. Ricketts, J.M. Verhaeg, I.J. Bujalska, A.J. Howie, W.E. Rainey, and P.M. Stewart J. Clin. Endocrinol. Metab. 1998 1325
8. C.B. Whorwood, C.B. Mason, M.L. Ricketts, A.J. Howie, and P.M. Stewart Mol. Cell. Endocrinol. 110 1995 R7
9. J.R. Seckl, and B.R. Walker Endocrinology 142 2001 1371
10. Y.V. Kotelevtsev, R.W. Brown, S. Fleming, C. Kenyon, C.R.W. Edwards, J.R. Seckl, and J.J. Mullins J. Clin. Invest. 103 1999 683
11. N.M. Morton, M.C. Holmes, C. Fiévet, B. Staels, A. Tailleux, J.J. Mullins, and J.R. Seckl J. Biol. Chem. 276 2001 41293
12. H. Masuzaki, J. Paterson, H. Shinyama, N.M. Morton, J.J. Mullins, J.R. Seckl, and J.S. Flier Science 294 2001 2166
13. E.E. Kershaw, N.M. Morton, H. Dhillon, L. Ramage, J.R. Seckl, and J.S. Flier Diabetes 1023 2005 54
14. P.C. White, T. Mune, and A.K. Agarwal Endocrinol. Rev. 18 1997 135
15. For reviews, see for example: C. Fotsch, B.C. Askew, and J.J. Chen Expert Opin. Therap. Pat. 15 2005 289
16. S.P. Webster, and T.D. Pallin Expert Opin. Therap. Pat. 17 2007 1407
17. C.D. Boyle Curr. Opin. Drug Discov. Devel. 11 2008 495
18. K.A. Hughes, S.P. Webster, and B.R. Walker Expert Opin. Investig Drugs 17 2008 481
19. C.D. Boyle, and T.J. Kowalski Expert Opin. Therap. Pat. 19 2009 801
20. R. Ge, Y. Huang, G. Liang, and X. Li Curr. Med. Chem. 17 2010 412
21. M.P. Thomas, and B.V. Potter Future Med. Chem. 3 2011 367
22. S. Singh, and C. Tice Curr. Pharm. Biotechnol. 11 2010 779
23. D. Sun, M. Wang, and Z. Wang Curr. Top. Med. Chem. 11 11 2011 1464
24. C. Abad-Zapatero, and J.T. Metz Drug Discov. Today 10 2005 464
25. B. Sorensen, M. Winn, J. Rohde, Q. Shuai, J. Wang, S. Fung, K. Monzon, W. Chiou, D. Stolarik, H. Imade, L. Pan, X. Deng, L. Chovan, K. Longenecker, R. Judge, W. Qin, M. Brune, H. Camp, E.U. Frevert, P. Jacobson, and J.T. Link Bioorg. Med. Chem. Lett. 17 2007 527
26. G. Jones, P. Willett, R.C. Glen, A.R. Leach, and R. Taylor J. Mol. Biol. 267 1997 727
27. M.L. Verdonk, J.C. Cole, M.J. Hartshorn, C.W. Murray, and R.D. Taylor Proteins 52 2003 609
28. C.W. Murray, T.R. Auton, and M.D. Eldridge J. Comput.-Aided Mol. Des. 12 1998 503
29. M.L. Verdonk, V. Berdini, M.J. Hartshorn, W.T.M. Mooij, C.W. Murray, R.D. Taylor, and P. Watson J. Chem. Inf. Comput. Sci. 44 2004 793
30. C.A. Hunter, and J.K.M. Sanders J. Am. Chem. Soc. 112 1990 5525
31. The structure of a humanised murine 11β-HSD1 with 6 point mutations (M175V, Q177Y, I180V, E226A, I227V, I231V) in complex with compound 22 and NADP(H) was generated. This mutant was designed with the aim to make the binding pocket more similar to the human isoform. The structure was solved at a resolution of 2.28, revealing the detailed binding mode of the ligand in the active site. The atomic coordinates have been deposited in the RCSB Protein Data Bank (www.rscb.org ) under accession code 3GMD.
32. J. Zhang, T.D. Osslund, M.H. Plant, C.L. Clogston, R.E. Nybo, F. Xiong, J.M. Delaney, and S.R. Jordan Biochemistry 44 2005 6948
33. K.W. Kim, Z. Wang, J. Busby, T. Tsuruda, M. Chen, C. Hale, V.M. Castro, S. Svensson, R. Nybo, F. Xiong, and M. Wang Biochim. Biophys. Acta 1764 2006 824
34. A.D. Favia, M. Masetti, M. Recanatini, and A. Cavalli PLoS One 6 2011 e25375